Hidden Protein Networks Emerge as Central Players in Huntington’s Disease

Huntington’s disease has long been portrayed as a story about one rogue protein. A mutated huntingtin gene, carrying an expanded stretch of CAG repeats on chromosome 4, produces a misfolded protein that clumps inside neurons, and those clumps were assumed to be the killers. A new review published in Molecular Biology Reports argues that this picture is far too simple. Chhavi Panwar, Falguni Goel and Vipin Kumar Garg of the Meerut Institute of Engineering and Technology synthesize evidence that Huntington’s disease is better understood as a systems-level breakdown: a web of protein-protein interactions that spans proteostasis, mitochondrial dynamics, energy metabolism, neuroinflammation, synaptic transmission, and transcriptional and epigenetic regulation, all destabilized by the mutant huntingtin protein.

The technical foundation for this shift in perspective comes from systems biology. By mining curated interaction databases such as STRING and BioGRID and visualizing the results in network analysis platforms like Cytoscape, researchers have assembled maps of the molecular relationships that mutant huntingtin disturbs. Rather than a single linear pathway from misfolded protein to cell death, these maps reveal interconnected modules whose failure propagates through the cell. Crucially, the analysis identifies hub proteins—highly connected nodes such as the molecular chaperone HSP70, the mitochondrial fission regulator DRP1, the inflammatory sensor NLRP3, and the autophagy-controlling transcription factor EB (TFEB)—that act as central control points linking otherwise separate pathways. When a hub fails, the damage radiates outward along many edges at once.

One of the clearest cascades described in the review begins with the ubiquitin-proteasome system, the cell’s primary machinery for shredding damaged or misfolded proteins. Mutant huntingtin impairs this system, so damaged proteins and organelles accumulate. The resulting burden drives mitochondrial oxidative stress: reactive oxygen species rise, ATP production falters, and damaged mitochondria release danger signals. Those signals activate the NLRP3 inflammasome, a multi-protein immune complex best known for igniting inflammation in immune cells. In the Huntington’s brain, chronic NLRP3 activation sustains microglial and astrocyte inflammatory responses, which in turn erode synaptic function. The end point of this cascade is the selective degeneration of medium spiny neurons in the striatum, the cell population whose loss produces the disease’s characteristic uncontrolled movements, psychiatric disturbances, and cognitive decline.

Proteostasis—the cell’s overall management of protein folding, trafficking, and degradation—emerges as a second major battleground. Beyond the ubiquitin-proteasome system, the review details how the autophagy-lysosomal pathway, the cell’s bulk recycling route, is compromised in Huntington’s disease. TFEB, the master transcriptional regulator of lysosomal and autophagy genes, sits at a critical node here; when its activity is suppressed, neurons cannot clear aggregates or damaged mitochondria efficiently. The endoplasmic reticulum adds another layer, with ER stress and ER-mitochondrial crosstalk amplifying the damage. Recent work on polyglutamine-mediated ribotoxicity suggests that the expanded protein tract disrupts proteostasis and stress responses even at the ribosome, meaning the folding crisis begins early in the protein’s life, long before visible aggregates form.

Mitochondrial dysfunction deserves particular attention because it connects nearly every other module in the network. Studies in patient-derived fibroblasts show compromised mitochondrial organization and structure, while DRP1, the dynamin-related protein that governs mitochondrial fission, is dysregulated in the disease. Broken fission-fusion balance means damaged mitochondria cannot be segregated and removed by mitophagy, the specialized autophagy of organelles. Energy metabolism collapses as a result, with the AMP-activated protein kinase and PGC1-alpha regulatory axes—both central to cellular energy sensing—falling out of tune. The review also highlights emerging cell-death mechanisms such as ferroptosis, an iron-dependent form of lipid peroxidation-driven death that links oxidative stress, mitochondria, and the selective vulnerability of striatal neurons.

Perhaps the most consequential claim in the review is temporal: faulty neuroplasticity develops before visible protein aggregates appear. Evidence from the R6/2 and YAC128 transgenic mouse models, from neurons derived from human induced pluripotent stem cells, and from multi-omics studies indicates that synaptic transmission and plasticity are impaired early in the disease course. Brain-derived neurotrophic factor, a growth factor critical for striatal neuron survival whose transport depends on normal huntingtin, is dysregulated long before overt neurodegeneration. RNA granules and RNA-binding proteins such as muscleblind-like protein 1 and ataxin-2 add further early-stage complexity, tying the mutant protein to defects in local translation at synapses. This early dysfunction reframes the therapeutic window: interventions may need to start decades before symptoms, targeting network imbalances rather than waiting to dissolve aggregates.

The network view also explains why genetic modifiers matter so much. Beyond the CAG repeat length, which only partially predicts age of onset, genome-wide studies have identified modifier genes concentrated in DNA repair and interaction-network hubs. Hyperbolic mapping of the protein interaction network and dynamic profiling of huntingtin’s interactions in the striatum have both pointed to candidate modifiers whose normal function buffers the network against the mutant protein’s perturbations. In this framing, disease severity reflects not just the toxic protein but the resilience—or fragility—of the surrounding interaction web, which varies between individuals and shifts with age.

Therapeutically, the review surveys strategies that target the hubs rather than the aggregate itself. Chaperone-based approaches aim to boost HSP70 and the heat shock response governed by HSF1. Selective NLRP3 inflammasome inhibitors have shown neuroprotection in transgenic mouse models, and modulation of the cGAS-STING innate immune pathway represents a newer anti-inflammatory frontier. TFEB activation and small molecules that engage the autophagy-lysosomal pathway, including a p75NTR modulator that reduced huntingtin aggregates in cellular and mouse models, aim to restore cellular clearance. Mitochondria-targeted strategies, from coenzyme Q10 supplementation to compounds that modulate mTORC1 and AMPK/SIRT1/ULK1 signaling, attempt to repair the energy backbone. Epigenetic therapies, notably histone deacetylase inhibitors such as suberoylanilide hydroxamic acid, target the transcriptional dysregulation that silences protective genes.

The most ambitious interventions aim at the source. Antisense oligonucleotides designed to lower mutant huntingtin production have moved from design into clinical testing, while adeno-associated virus-mediated gene therapy approaches are advancing rapidly. The review notes that these nucleic-acid strategies could be combined with network-targeting small molecules, attacking the disease at both its genetic origin and its downstream systems-level consequences. Repurposed drugs, including the tetracycline antibiotic minocycline for its anti-inflammatory effects, and natural compounds such as resveratrol and morin that activate autophagy and antioxidant pathways, illustrate the breadth of the current pipeline.

What makes this review significant is not a single discovery but a change in the map. Huntington’s disease, on this evidence, is a network disorder in which a single expanded protein destabilizes chaperones, proteasomes, mitochondria, inflammasomes, synapses, and chromatin simultaneously—and the hubs that tie these systems together, HSP70, DRP1, NLRP3, and TFEB, are the most promising points of intervention. The authors caution that no datasets were newly generated in their analysis; it is a synthesis, and its power lies in connecting dots across mouse models, human stem-cell systems, and omics data. If the network view holds up in clinical testing, the future of Huntington’s therapy may lie not in one miracle molecule but in combination treatments that hold the entire web together, started early enough to matter.

Subject of Research: Protein-protein interaction networks in Huntington's disease pathogenesis and therapy

Article Title: Uncovering hidden protein networks in Huntington’s disease: implications for pathogenesis and therapy

Article References: Panwar, C., Goel, F., & Garg, V. K. (2026). Uncovering hidden protein networks in Huntington’s disease: implications for pathogenesis and therapy. Molecular Biology Reports, 53(1), Article 1626. https://doi.org/10.1007/s11033-026-12823-6

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12823-6

Keywords: Huntington's disease, mutant huntingtin, protein-protein interaction networks, proteostasis, ubiquitin-proteasome system, autophagy, mitochondrial dysfunction, NLRP3 inflammasome, neuroinflammation, synaptic dysfunction, TFEB, gene therapy